Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

The ErbB signaling network: receptor heterodimerization in development and cancer.

Olayioye MA, Neve RM, Lane HA, Hynes NE.

EMBO J. 2000 Jul 3;19(13):3159-67. Review. No abstract available.

2.
3.

Signal transduction and oncogenesis by ErbB/HER receptors.

Marmor MD, Skaria KB, Yarden Y.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13. Review.

PMID:
14967450
4.
5.

Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer.

Rizzo P, Osipo C, Pannuti A, Golde T, Osborne B, Miele L.

Adv Enzyme Regul. 2009;49(1):134-41. doi: 10.1016/j.advenzreg.2009.01.008. Epub 2009 Jan 20. Review. No abstract available.

PMID:
19344631
7.

Role of HER receptors family in development and differentiation.

Casalini P, Iorio MV, Galmozzi E, Ménard S.

J Cell Physiol. 2004 Sep;200(3):343-50. Review.

PMID:
15254961
8.

Role of HER2/HER3 co-receptor in breast carcinogenesis.

Way TD, Lin JK.

Future Oncol. 2005 Dec;1(6):841-9. Review.

PMID:
16556064
10.

Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.

Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K.

Breast Cancer Res Treat. 2003 Aug;80(3):353-61.

PMID:
14503808
11.
12.

Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.

Menendez JA, Schroeder B, Peirce SK, Vellon L, Papadimitropoulou A, Espinoza I, Lupu R.

J Natl Cancer Inst. 2015 Apr 16;107(6):djv090. doi: 10.1093/jnci/djv090. Print 2015 Jun.

PMID:
25888715
13.

Bivalence of EGF-like ligands drives the ErbB signaling network.

Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y.

EMBO J. 1997 Aug 15;16(16):4938-50.

15.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.

16.

ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE.

Mol Cell Biol. 1998 Sep;18(9):5042-51.

18.

Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.

Bancovik J, Moreira DF, Carrasco D, Yao J, Porter D, Moura R, Camargo A, Fontes-Oliveira CC, Malpartida MG, Carambula S, Vannier E, Strauss BE, Wakamatsu A, Alves VA, Logullo AF, Soares FA, Polyak K, Belizário JE.

BMC Cancer. 2015 Feb 19;15:70. doi: 10.1186/s12885-015-1022-6.

19.

Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.

Sak MM, Szymanska M, Bertelsen V, Hasmann M, Madshus IH, Stang E.

Carcinogenesis. 2013 Sep;34(9):2031-8. doi: 10.1093/carcin/bgt173. Epub 2013 May 22.

PMID:
23698633
20.

Supplemental Content

Support Center